Get the Stockscreener App
2.14
7.54%
0.15
After Hours:
2.14
Editas Medicine Inc stock is traded at $2.14, with a volume of 2.39M.
It is up +7.54% in the last 24 hours and down -11.57% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$1.99
Open:
$2.01
24h Volume:
2.39M
Relative Volume:
1.07
Market Cap:
$208.90M
Revenue:
$32.31M
Net Income/Loss:
$-237.09M
P/E Ratio:
-0.7431
EPS:
-2.88
Net Cash Flow:
$-219.11M
1W Performance:
+4.90%
1M Performance:
-11.57%
6M Performance:
-16.73%
1Y Performance:
+49.65%
1-Day Range:
$1.995
$2.15
1-Week Range:
$1.95
$2.15
52-Week Range:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.14 | 194.26M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fibonacci Retracement Aligns with Support in Alka Securities LimitedMarket Sentiment Shifts & Free Realize Exceptional Returns - earlytimes.in
Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9%Should You Sell? - MarketBeat
Editas Medicine (EDIT) price target increased by 22.78% to 4.95 - MSN
Can Editas Medicine Inc. stock attract ESG capital inflowsPortfolio Growth Summary & High Win Rate Trade Tips - Улправда
Is Editas Medicine Inc. stock overvalued by current metricsGap Up & Reliable Trade Execution Plans - Улправда
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN
Can Editas Medicine Inc. stock surprise with earnings upsideJuly 2025 Patterns & Fast Exit and Entry Trade Guides - Улправда
Editas Medicine Earnings Notes - Trefis
What margin trends mean for Editas Medicine Inc. stockIPO Watch & Weekly Chart Analysis and Guides - DonanımHaber
How Editas Medicine Inc. stock compares to growth peersPortfolio Profit Report & Precise Entry and Exit Recommendations - Bölüm Sonu Canavarı
Is Editas Medicine Inc. stock affected by interest rate hikes2025 Market Outlook & Free Technical Pattern Based Buy Signals - DonanımHaber
Is Editas Medicine Inc. stock in correction or buying zoneJuly 2025 Catalysts & Expert Curated Trade Setups - DonanımHaber
Why Editas Medicine Inc. stock is seen as undervaluedOptions Play & Advanced Swing Trade Entry Alerts - DonanımHaber
Editas Medicine (LTS:0IFK) EV-to-FCF : -0.48 (As of Dec. 18, 2025) - GuruFocus
S P Trends: How Editas Medicine Inc stock compares to growth peersWeekly Profit Recap & Consistent Profit Trading Strategies - moha.gov.vn
Editas Medicine (FRA:8EM) EV-to-OCF : -0.45 (As of Dec. 18, 2025) - GuruFocus
Market Rankings: What margin trends mean for Editas Medicine Inc. stockIPO Watch & Capital Efficiency Focused Strategies - moha.gov.vn
Editas (EDIT) down 8.3% since last earnings report: Can it rebound? - MSN
What analysts say about Editas Medicine Inc stockTechnology Stock Trends & Small Budget Trading Plans - earlytimes.in
Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound? - sharewise.com
Cell & Gene Therapy Market to Reach USD 105.83 Billion by 2033 - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Editas Medicine (EDIT) Price Target Increased by 22.78% to 4.95 - Nasdaq
Editas Medicine (EDIT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock - MarketBeat
Trend Recap: Is Editas Medicine Inc. (8EM) stock supported by free cash flowJuly 2025 Patterns & High Accuracy Swing Trade Signals - moha.gov.vn
What valuation ratios show for Editas Medicine Inc. (8EM) stockEarnings Summary Report & Reliable Intraday Trade Alerts - Newser
CEO O'Neill Surrenders 5,603 Of Editas Medicine Inc [EDIT] - TradingView
Editas Medicine CEO Sells Shares to Meet Tax Obligations - TradingView
How Editas Medicine Inc. (8EM) stock performs in easing cyclesJuly 2025 Selloffs & Safe Entry Momentum Tips - Newser
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Will Editas Medicine Inc. (8EM) stock beat Nasdaq index returns2025 Pullback Review & Free Verified High Yield Trade Plans - Newser
Is Editas Medicine Inc. (8EM) stock positioned for digital growth eraMarket Growth Summary & Free Fast Gain Swing Trade Alerts - Newser
CEO O'Neill Files To Sell 7,000 Of Editas Medicine Inc [EDIT] - TradingView
Euro India Fresh Foods Limited Forms Bullish Flag Upside AheadCovered Call Writing & Learn From the Strategies of Institutions - earlytimes.in
FY2025 EPS Estimates for Editas Medicine Lowered by Analyst - MarketBeat
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat
Portfolio Shifts: Is Editas Medicine Inc. stock a bargain at current levelsMarket Activity Recap & Fast Moving Stock Trade Plans - moha.gov.vn
Editas (EDIT) Q2 2024 Earnings Call Transcript - The Globe and Mail
Editas Medicine Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Access Free Risk Analysis Before You Invest - earlytimes.in
Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates - MSN
Editas Medicine price target raised to $4.60 from $4 at Clear Street - MSN
Is Editas Medicine Inc. (8EM) stock overpriced at current multiplesPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Is Editas Medicine Inc. (8EM) stock in buy zone after pullbackJuly 2025 Rallies & AI Powered Market Entry Strategies - newser.com
Will Editas Medicine Inc. (8EM) stock gain from green policies2025 Big Picture & Technical Confirmation Alerts - newser.com
Will Editas Medicine Inc. stock continue upward momentumForecast Cut & Free Technical Pattern Based Buy Signals - newser.com
How Editas Medicine Inc. (8EM) stock responds to job market shiftsJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com
Can Editas Medicine Inc. stock sustain market leadershipQuarterly Risk Review & Weekly Chart Analysis and Trade Guides - newser.com
Is Editas Medicine Inc. (8EM) stock expanding market penetrationFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Does Editas Medicine Inc. (8EM) stock trade below intrinsic valueQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Editas Medicine Inc Stock (EDIT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'Neill Gilmore Neil | CEO |
Dec 03 '25 |
Sale |
2.15 |
5,603 |
12,064 |
269,087 |
| Parison Amy | SVP, Chief Financial Officer |
Dec 03 '25 |
Sale |
2.15 |
461 |
993 |
15,908 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):